Premenopausal women with recurrent urinary tract infections have lower quality of life

2018 ◽  
Vol 25 (7) ◽  
pp. 684-689 ◽  
Author(s):  
Siobhan S Ennis ◽  
Huifang Guo ◽  
Lata Raman ◽  
Paul A Tambyah ◽  
Swaine L Chen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Premenopausal Women ◽  
Recurrent Urinary Tract Infections ◽  
Tract Infections

scholarly journals Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: Results from a multicentre survey

2014 ◽  
Vol 8 (9-10) ◽  
pp. 721 ◽  
Author(s):  
Antonio Cicione ◽  
Francesco Cantiello ◽  
Giuseppe Ucciero ◽  
Andrea Salonia ◽  
Marco Torella ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hyaluronic Acid ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Chondroitin Sulphate ◽  
Recurrent Utis ◽  
Recurrent Urinary Tract Infections ◽  
Tract Infections

Introduction: We assess the effectiveness of intravesical instillation of hyaluronic acid (HA) and chondroitin sulphate (CS) as a non-antibiotic treatment option for prophylaxis of recurrent urinary tract infections (UTIs) in female patients.Methods: This was a retrospective cohort study involving 7 European institutions. We included patients with recurrent UTIs who received intravesical instillations of Ialuril (IBSA International) (50 mL HA 1.6% and CS 2% solution) between January 2010 and March 2012. Medication schedule, length of follow-up, recurrence infection time, number of UTIs/patients/year, patient quality of life, subjective symptoms score, and treatment-emergent side effects were recorded and analyzed.Results: In total, 157 women (mean age: 54.2 ± 4.1 years) were included in the analysis. All patients had at least 12 months follow-up. After 4 weekly and 5 monthly HA-CS bladder instillations, UTI episodes decreased from 4.13 ± 1.14 to 0.44 ± 0.50 (p = 0.01) at 12 months, while recurrent UTI time prolonged from 94.8 ± 25.1 days to 178.4 ± 37.3 days (p = 0.01) at 12 months. An improvement in symptoms and quality of life was achieved. A medium-depth pain after medication instillation was the most reported side effect. Regression model analysis showed significant risk factors in developing new UTI episodes: being more than 50 years old and having more than 4 UTI episodes per year (OR 3.41; CI 95%; 1.51-7.71, p = 0.003 and OR 3.31; CI 95% 1.51-7.22; p = 0.003, respectively). Retrospective design and lack of a control group represent two main limitations of the study.Conclusions: Restoring glycosaminoglycans bladder layer therapy is a promising non-antibiotic therapy to prevent recurrent UTIs.

scholarly journals Impact of Recurrent Urinary Infections on the Quality of Life of Women in Outpatient Care: a Case-control Study

2021 ◽  
Author(s):  
Luciano Garcia Lourenção ◽  
Jacqueline Flores de Oliveira ◽  
José Carlos Carraro Eduardo ◽  
Giovani Machado Homem ◽  
Carlos Augusto Faria
Keyword(s):  
Quality Of Life ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Case Control Study ◽  
Case Control ◽  
World Health ◽  
Recurrent Urinary Tract Infections ◽  
Tract Infections ◽  
Control Study

Abstract Background: The repetitive urinary tract infections impact women's quality of life and represent an important problem for women's physical and mental health, causing relevant social impacts. This study aimed to evaluate the impact of recurrent urinary tract infections on the quality of life of women with recurrent infections.Methods: This is a case-control study with 49 women with recurrent urinary tract infections, confirmed by urine culture, without complications and 49 women without recurrent urinary tract infections, seen at an outpatient clinic of a public teaching hospital in the city of Niterói, Rio de Janeiro, Brazil. Quality of life was evaluated using the Brazilian version of the World Health Organization's shortened questionnaire, the WHOQOL-Bref.Results: Women with urinary tract infections showed greater impairment of quality of life in the physical (p = 0.007) and psychological (p = 0.038) domains, with lower quality of life score in their self-assessment (p = 0.002), when compared to the group control. Women with recurrent urinary infection had mean scores significantly lower than the control group in the Energy and fatigue (p = 0.003), Positive feelings (p = 0.014), Self-esteem (p = 0.040), Dependence on medication (p = 0.029), Negative feelings (p = 0.023) and Recreation and leisure (p = 0, 0.041).Conclusions: Recurrent urinary tract infections have an important impact on the quality of life of women, especially in the Physical and Psychological domains, representing a significant problem for women, health professionals, and the health system.

scholarly journals D-MannosE to prevent Recurrent urinary tract InfecTions (MERIT): protocol for a randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. e037128
Author(s):  
Marloes Franssen ◽  
Johanna Cook ◽  
Jared Robinson ◽  
Nicola Williams ◽  
Margaret Glogowska ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Negative Impact ◽  
Controlled Trial ◽  
Pragmatic Trial ◽  
Double Blind ◽  
Recurrent Urinary Tract Infections ◽  
Tract Infections

IntroductionRecurrent urinary tract infections (RUTIs) have a significant negative impact on quality of life and healthcare costs. To date, daily prophylactic antibiotics are the only treatment which have been shown to help prevent RUTIs. D-mannose is a type of sugar which is believed to inhibit bacterial adherence to uroepithelial cells, and is already being used by some women in an attempt to prevent RUTIs. There is currently insufficient rigorous evidence on which to base decisions about its use. The D-mannose to prevent recurrent urinary tract infections (MERIT) study will evaluate whether D-mannose is clinically and cost-effective in reducing frequency of infection and symptom burden for women presenting to UK primary care with RUTI.Methods and analysisMERIT will be a two-arm, individually randomised, double blind placebo controlled, pragmatic trial. Participants will be randomised to take D-mannose powder or placebo powder daily for 6 months. The primary outcome will be the number of medical attendances attributable to symptoms of RUTI. With 508 participants we will have 90% power to detect a 50% reduction in the chance of a further clinically suspected UTI, assuming 20% lost to follow-up. Secondary outcomes will include: number of days of moderately bad symptoms of UTI; time to next consultation; number of clinically suspected UTIs; number of microbiologically proven UTIs; number of antibiotic courses for UTI; quality of life and healthcare utilisation related to UTI. A within trial economic evaluation will be conducted to examine cost-effectiveness of D-mannose in comparison with placebo. A nested qualitative study will explore participants’ experiences and perceptions of recruitment to, and participation in a study requiring a daily treatment.Ethics and disseminationEthical approval has been obtained from South West-Central Bristol Research Ethics Committee. Publication of the MERIT study is anticipated to occur in 2021.Trial registration numberISRCTN 13283516.

W069 RECURRENT LOWER URINARY TRACT INFECTIONS HAVE A DETRIMENTAL EFFECT ON PATIENT QUALITY-OF-LIFE

2012 ◽  
Vol 119 ◽  
pp. S727-S727
Author(s):  
J. Renard ◽  
M.T. Da Quinta e Costa de Mascarenhas Sa ◽  
G.J. Wirth ◽  
M. Zahran ◽  
E. Quimper ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Lower Urinary Tract ◽  
Detrimental Effect ◽  
Tract Infections ◽  
Lower Urinary
Sign in / Sign up

Export Citation Format

Share Document